Semaglutide vs Tirzepatide: Diabetes and Weight Loss

Research-informed explainer — last updated 2026-04-11

Both semaglutide and tirzepatide lower blood sugar and cause significant weight loss in people with type 2 diabetes — but tirzepatide consistently shows larger effects on both measures, while semaglutide has a longer cardiovascular outcomes track record. For most patients with type 2 diabetes, the choice comes down to how much weight loss matters, whether you have established heart disease, and what your insurance covers.

This explainer draws on peer-reviewed research from four endocrinologists in the Convene directory whose published work spans the foundational clinical trials for both drugs: a lead investigator on the STEP and SUSTAIN semaglutide trials, a co-investigator on the SURMOUNT-2 tirzepatide trial, a co-investigator on SURPASS-4 comparing tirzepatide to insulin in high-risk patients, and a co-architect of the ADA/EASD consensus guidelines that now guide clinical practice.

How each drug works

Both drugs are once-weekly injections that mimic gut hormones your body already makes.

Semaglutide (sold as Ozempic for type 2 diabetes) mimics a hormone called GLP-1 (glucagon-like peptide-1). GLP-1 prompts your pancreas to release insulin when blood sugar rises, suppresses a hormone called glucagon that would otherwise raise blood sugar, slows how quickly food leaves your stomach, and signals your brain to feel full. It has been available since 2017 and has a well-established safety record.

Tirzepatide (sold as Mounjaro for type 2 diabetes) does everything semaglutide does and adds a second hormone: GIP (glucose-dependent insulinotropic polypeptide). GIP appears to amplify the weight loss signal and may also contribute to greater insulin secretion. That dual mechanism — GLP-1 plus GIP — is why tirzepatide tends to produce larger reductions in both A1c and body weight than semaglutide.

At a glance

What the semaglutide trials showed

The pivotal cardiovascular trial for semaglutide in type 2 diabetes is SUSTAIN-6, published in the New England Journal of Medicine in 2016. It enrolled 3,297 patients with type 2 diabetes at high cardiovascular risk. Patients on semaglutide had a 26% lower rate of major cardiovascular events — heart attack, stroke, or cardiovascular death — than those on placebo (HR 0.74) [1]. This was the first large outcomes trial establishing semaglutide's cardiovascular benefit in a diabetic population.

For weight loss specifically in people with type 2 diabetes, the STEP 2 trial — a randomized, double-blind, placebo-controlled study — tested the higher 2.4 mg dose. Patients with type 2 diabetes and obesity lost an average of 9.6% of their body weight at 68 weeks, compared to 3.4% with placebo [4]. In head-to-head work, SUSTAIN 7 found that semaglutide 1 mg outperformed dulaglutide 1.5 mg on both A1c reduction and weight loss, cementing semaglutide's position at the top of the GLP-1 class before tirzepatide arrived [5].

Semaglutide also has landmark cardiovascular data in people with obesity but without diabetes. The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled 17,604 people with established cardiovascular disease and obesity but no diabetes. Over a mean 39.8 months of follow-up, semaglutide 2.4 mg reduced major cardiovascular events by 20% compared to placebo [3]. No other weight-loss medication had shown that outcome before.

What the tirzepatide trials showed

The SURMOUNT-2 trial, published in The Lancet in 2023, is the clearest evidence for tirzepatide in people with type 2 diabetes and obesity. Patients taking tirzepatide 10 mg lost an average of 13.9% of their body weight, and those taking 15 mg lost 15.7%, compared to 3.3% with placebo [7]. Those are the largest weight losses recorded in a randomized phase 3 trial in this specific population — roughly 5–6 percentage points more than semaglutide achieved in STEP 2.

The SURPASS-4 trial provides important context for patients with type 2 diabetes who also have elevated cardiovascular risk. This randomized trial compared tirzepatide to insulin glargine in over 2,000 patients with type 2 diabetes and high cardiovascular risk. Tirzepatide produced greater A1c reduction, greater weight loss, and lower rates of hypoglycemia than insulin glargine [8]. For patients who might otherwise require insulin, this positions tirzepatide as a compelling alternative — though direct cardiovascular outcomes data for tirzepatide in diabetic patients is still pending from SURPASS-CVOT.

Earlier evidence comparing GLP-1 agents to insulin-based approaches set the stage for these trials. A 2015 randomized study in JAMA showed that liraglutide — an older GLP-1 agonist — produced clinically meaningful weight loss in type 2 diabetes patients who had not reached goals with standard oral therapy [6]. Tirzepatide has since exceeded those benchmarks substantially.

Blood sugar control: where the numbers land

For most people with type 2 diabetes, the primary goal is lowering hemoglobin A1c — the three-month blood sugar average that predicts long-term complications.

In the SUSTAIN and STEP trials, semaglutide consistently reduced A1c by approximately 1.5–1.8 percentage points from baseline in patients with type 2 diabetes. In STEP 2, the trial specifically in patients with T2D and obesity, the reduction was about 1.6% [4].

Tirzepatide's A1c reductions are larger across the board. In the SURPASS program, the 15 mg dose cut A1c by up to 2.6 percentage points. SURPASS-2 compared tirzepatide directly to semaglutide 1 mg — the standard Ozempic dose — and at all three tirzepatide doses, A1c reduction was statistically significantly greater than with semaglutide.

In practical terms: if your starting A1c is 8.5%, semaglutide might bring you to around 6.9%, while tirzepatide 15 mg might bring you to around 5.9% — potentially below the 6.5% threshold that defines remission. That kind of difference can matter for patients trying to avoid insulin or reverse the trajectory of their disease.

Weight loss in type 2 diabetes: the gap is substantial

Weight loss and blood sugar control are deeply linked. Losing 10–15% of body weight in type 2 diabetes can reduce insulin resistance, improve lipid profiles, lower blood pressure, and in some patients achieve diabetes remission.

Semaglutide at the 2.4 mg dose (Wegovy, which is higher than the standard Ozempic dose) produced 9.6% weight loss in STEP 2 — meaningful, but constrained partly because the people in that trial had type 2 diabetes, which blunts GLP-1's full weight loss effect compared to people without diabetes [4].

Tirzepatide broke through that ceiling. SURMOUNT-2 showed 13.9–15.7% weight loss in the same population type, with more than a third of patients losing 20% or more of their body weight at the highest dose [7]. For someone weighing 270 pounds, a 15% loss means 40 pounds. A 20% loss means 54 pounds. These are numbers that can meaningfully change someone's health trajectory.

Cardiovascular outcomes: semaglutide's lasting advantage

The most clinically significant difference between the two drugs — for patients with established heart disease — is how much cardiovascular outcomes data each one has.

Semaglutide has eight years of completed outcomes data. SUSTAIN-6 showed a 26% reduction in MACE in type 2 diabetes patients at high cardiovascular risk [1]. SELECT extended that to people with obesity and no diabetes, showing a 20% MACE reduction [3]. These are completed, peer-reviewed randomized trials with tens of thousands of patients. They are the foundation for current guidelines recommending GLP-1 agents for people with type 2 diabetes and cardiovascular disease.

The ADA/EASD 2018 consensus statement, which John Buse at the University of North Carolina co-led, formalized this into clinical guidance: for patients with established cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular benefit should be preferred regardless of baseline A1c [9]. The 2022 update reinforced this framework while integrating newer agents, noting that the selection of specific drugs should be individualized based on comorbidities, patient priorities, and access [10].

Tirzepatide has no completed cardiovascular outcomes trial as of April 2026. SURPASS-CVOT is ongoing. Favorable surrogate markers — weight loss, blood pressure reduction, lipid improvement — are encouraging, but they are not the same as hard outcomes data. For a patient with a recent heart attack, stroke, or heart failure, that gap in evidence matters to the prescribing endocrinologist.

When each drug tends to be preferred

These patterns reflect how trial data is currently applied in clinical practice — your specific situation should drive the actual decision.

Tirzepatide tends to be a stronger choice when:

• Weight loss is a primary goal alongside blood sugar control
• Your A1c is well above target and you need the largest possible reduction
• You do not have established cardiovascular disease
• You might otherwise need insulin — the SURPASS-4 data is directly relevant
• Your insurance covers it on a favorable tier

Semaglutide tends to be a stronger choice when:

• You have established cardiovascular disease (prior heart attack, stroke, or symptomatic atherosclerosis)
• You or your doctor want proven MACE reduction from a completed outcomes trial
• You prefer an oral option — Rybelsus is the daily tablet form approved for type 2 diabetes
• Insurance coverage or cost strongly favors it
• You have previously responded well to another GLP-1 agonist

Side effects

Both drugs share a similar side effect profile driven by their GLP-1 mechanism. The most common complaints are nausea, vomiting, diarrhea, and constipation. These are most pronounced when starting or escalating the dose and usually improve after a few weeks at a stable dose. Both medications are titrated slowly over several months specifically to reduce this problem.

Neither drug is appropriate for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both carry class warnings about pancreatitis and gallbladder disease. Your endocrinologist will review your full medical history before prescribing either.

At higher doses, tirzepatide's gastrointestinal side effects may be somewhat more common than semaglutide's — a trade-off for its larger metabolic effect.

Questions to ask your endocrinologist

• Given my A1c and weight, which drug is more likely to help me reach my treatment goals?
• Do I have cardiovascular disease or risk factors that make the SUSTAIN-6 outcomes data directly relevant to my choice?
• What is the dose escalation schedule, and how long before we know if the drug is working?
• If I do not tolerate one drug's side effects, how different is the other likely to feel?
• Is insulin still on the table for me, and how does tirzepatide compare to it for my situation?
• What does my insurance cover, and what savings programs are available?

The bottom line

Tirzepatide produces greater A1c reduction and meaningfully greater weight loss than semaglutide in type 2 diabetes — the clinical data consistently shows this across the SURPASS and SURMOUNT programs. For patients whose primary challenge is reaching A1c targets, losing substantial weight, or avoiding insulin, tirzepatide has the stronger metabolic profile.

But semaglutide holds an advantage tirzepatide cannot yet match: completed cardiovascular outcomes data showing real reductions in heart attacks and strokes. For patients with established cardiovascular disease, that evidence — built across SUSTAIN-6 and SELECT — remains the clinical foundation for choosing semaglutide. An endocrinologist who knows your full history is best positioned to weigh those tradeoffs for your situation.